New Strong Sell Stocks for Dec. 17

Zacks added Avanos Medical (AVNS), Archer-Daniels-Midland (ADM) and Bank OZK (OZK) to its Zacks Rank #5 (Strong Sell) list after downward revisions to consensus earnings estimates over the past 60 days—AVNS -3.3%, ADM -8.6% and OZK -3.4%—indicating weakening near‑term earnings prospects, with ADM showing the most pronounced revision and thus the greatest potential downside risk among the three. The moves signal analyst concern that could translate into pressure on share performance if revisions continue or are confirmed by upcoming results.

Analysis

Zacks added Avanos Medical (AVNS), Archer‑Daniels‑Midland (ADM) and Bank OZK (OZK) to its Zacks Rank #5 (Strong Sell) list; the Zacks Consensus Estimate for current‑year earnings was revised downward over the past 60 days by 3.3% for AVNS, 8.6% for ADM and 3.4% for OZK. The Rank #5 designation signals analyst skepticism about near‑term fundamentals for each company.

The magnitude of the cuts is uneven: ADM’s 8.6% downward revision stands out and corresponds with the most negative per‑ticker sentiment score (-0.6), suggesting a higher probability of near‑term earnings disappointment or heightened commodity/volume exposure; AVNS and OZK recorded smaller but meaningful estimate declines (both with per‑ticker sentiment of -0.4). These revisions indicate shrinking near‑term earnings expectations rather than company‑confirming results at this stage.

Aggregate sentiment is moderately negative (sentiment score -0.4) and Zacks’ market impact score of 0.25 implies this list addition is unlikely to move markets broadly, but continued downward revisions or weak upcoming reports would likely pressure share prices and validate the strong‑sell rankings. Investors should therefore treat these signals as early warning indicators and prioritize incoming earnings, guidance and subsequent estimate trends as the key drivers of near‑term price action.

Key Decisions for Investors

• Reduce or avoid initiating new exposure to ADM until analyst estimates stabilize or the next earnings report provides evidence of earnings recovery given the 8.6% consensus cut and the most negative per‑ticker sentiment
• Trim or hedge existing positions in AVNS and OZK or implement downside protection, as both show ~3.3%–3.4% earnings downgrades and moderately negative sentiment that could translate into near‑term share pressure
• Monitor upcoming earnings, management guidance and subsequent estimate revisions closely and be prepared to reassess positions if downward revisions persist or, conversely, to consider re‑entry only after clear stabilization in analyst estimates